Advanced/Metastatic Solid Tumors research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE1, PHASE2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This study is looking at a new drug called MCLA-158 for advanced cancers like bowel and head and neck cancer. It aims to find the safest dose and see how well it works alone or with other treatments. It's for patients whose cancer has spread or come back.
United States · Belgium · France - recruitingPHASE1, PHASE2
Study for AZD4360 in Participants With Advanced Solid Tumours
This study is testing a new drug, AZD4360, for people with advanced stomach, bile duct, or pancreatic cancers that have a specific marker called CLDN18.2. It aims to see how safe it is and if it helps shrink tumors.
United States · China · Germany - recruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
United States · Australia · Canada - active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
United States · Brazil · Canada - recruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
United States · Argentina · Australia